Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Y5AM
|
||||
| Former ID |
DAP001131
|
||||
| Drug Name |
Darifenacin
|
||||
| Synonyms |
Emselex; Emselex (TN); Enablex (TN); Darifenacin (USAN/INN); (S)-1-(2-(2,3-Dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide; 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide; 2-{(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Overactive bladder disorder [ICD9: 188, 596.51; ICD10:C67, N32.81] | Approved | [1], [2], [3] | ||
| Therapeutic Class |
Urinary antispasmodics
|
||||
| Company |
Norvatis Phamaceuticals Corporation
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C28H30N2O2
|
||||
| InChI |
InChI=1S/C28H30N2O2/c29-27(31)28(23-7-3-1-4-8-23,24-9-5-2-6-10-24)25-14-17-30(20-25)16-13-21-11-12-26-22(19-21)15-18-32-26/h1-12,19,25H,13-18,20H2,(H2,29,31)/t25-/m1/s1
|
||||
| InChIKey |
HXGBXQDTNZMWGS-RUZDIDTESA-N
|
||||
| CAS Number |
CAS 133099-04-4
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7979027, 10944518, 14856314, 17397751, 36887144, 46508104, 50070895, 50113277, 50275204, 81145912, 85083117, 85583237, 92719451, 103435149, 104004586, 104631174, 126620787, 126651550, 128126220, 134338376, 135030473, 135650160, 135651146, 136947991, 137004287, 142807983, 144240344, 152047381, 160963842, 163621141, 163686486, 164826587, 175268333, 179149827, 186007015, 196107254, 223541474, 223831811, 226439188, 241032006, 249858507, 251916719, 251917958, 252215250
|
||||
| SuperDrug ATC ID |
G04BD10
|
||||
| Target and Pathway | |||||
| Target(s) | Muscarinic acetylcholine receptor M3 | Target Info | Antagonist | [4] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Cholinergic synapse | |||||
| Regulation of actin cytoskeleton | |||||
| Insulin secretion | |||||
| Salivary secretion | |||||
| Gastric acid secretion | |||||
| Pancreatic secretion | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||||
| PathWhiz Pathway | Gastric Acid Production | ||||
| Reactome | Muscarinic acetylcholine receptors | ||||
| Acetylcholine regulates insulin secretion | |||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Integration of energy metabolism | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, Other | |||||
| References | |||||
| REF 1 | 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4. | ||||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
| REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 321). | ||||
| REF 4 | M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5. Epub 2009 Feb 5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.